5,8,13,13a-tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline | 77638-87-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 原小檗碱生物碱及其衍生物
• 英文名称: 5,8,13,13a-tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline
• 英文别名: 5,8,13,13a-Tetrahydro-6H-[1,3]dioxolo[4,5-g]isochino[3,2-a]isochinolin；2,3-Methylendioxy-tetrahydro-protoberberin, 2,3-Methylendioxy-protoberberin；2,3-Methylendioxy-tetrahydro-protoberberin；5,7-Dioxa-13-azapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15,17,19-hexaene
• CAS: 77638-87-0
• 化学式: C₁₈H₁₇NO₂
• 分子量: 279.338
• InChiKey: WXMBJZSEIYAGMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5,8,13,13a-tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline 、 alkaline earth salt of/the/ methylsulfuric acid 反应 2.0h， 以86%的产率得到13-Benzyl-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-2,4(8),9,15,17,19-hexaene
  参考文献：
  名称：

  Synthesis and antihyperglycemic evaluation of various protoberberine derivatives

  摘要：

  Various berberine derivatives (2-17) were synthesized and their antihyperglycemic activities were evaluated in a model of beta-cell-membrane chromatography and a model of alloxan-induced diabetes mice. The results indicated that compounds 5 and 14 exhibited antihyperglycemic activity. Their structure-activity relationships were discussed. (C) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.045
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 硫酸 作用下， 生成 5,8,13,13a-tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline
  参考文献：
  名称：

  Haworth; Perkin; Pink, Journal of the Chemical Society, 1925, vol. 127, p. 1720

  摘要：

  DOI：

文献信息

• [EN] NOVEL ISOQUINOLINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'ISOQUINOLÉINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010128061A1

  公开（公告）日：2010-11-11

  A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R7 have the significance given in claim 1, can be used in the form of a pharmaceutical composition.

  化合物的结构式（I）或其药学上可接受的盐，其中R1至R7具有权利要求书中给定的含义，可用作药物组合物的形式。
• Exploratory, mechanistic, and synthetic aspects of silylarene-iminium salt SET photochemistry. Studies of diradical cyclization processes and applications to protoberberine alkaloid synthesis
  作者：Ginny Dai-Ho、Patrick S. Mariano

  DOI：10.1021/jo00256a038

  日期：1988.10
• DAI-HO, GINNY;MARIANO, PATRICK S., J. ORG. CHEM., 53,(1988) N 21, C. 5113-5127
  作者：DAI-HO, GINNY、MARIANO, PATRICK S.

  DOI：——

  日期：——
• NOVEL ISOQUINOLINE DERIVATIVES
  申请人：F.Hoffmann-La Roche AG

  公开号：EP2427460A1

  公开（公告）日：2012-03-14
• COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS
  申请人：Liu Haiyan

  公开号：US20120004223A1

  公开（公告）日：2012-01-05

  The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.